- ISIN DE000A3CMGM5
- Country Deutschland
Latest Research
News Functions
Additional Functions
13 November 2024
APONTIS PHARMA AG
Original-Research: APONTIS PHARMA AG (von Montega AG): Verkaufen (zuvor: Halten)
18 October 2024
APONTIS PHARMA AG
Original-Research: APONTIS PHARMA AG (von Montega AG): Halten (zuvor: Kaufen)
16 August 2024
APONTIS PHARMA AG
Original-Research: APONTIS PHARMA AG (von First Berlin Equity Research GmbH): BUY
12 August 2024
APONTIS PHARMA AG
Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen
24 June 2024
APONTIS PHARMA AG
Original-Research: APONTIS PHARMA AG (von First Berlin Equity Research GmbH): Buy
15 May 2024
APONTIS PHARMA AG
Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen
15 April 2024
APONTIS PHARMA AG
Original-Research: Apontis Pharma AG (von Montega AG): Kaufen
9 February 2024
APONTIS PHARMA AG
Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen
14 November 2023
APONTIS PHARMA AG
Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen
31 July 2023
APONTIS PHARMA AG
Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen
12 July 2023
APONTIS PHARMA AG
Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen
10 May 2023
APONTIS PHARMA AG
Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen
4 May 2023
APONTIS PHARMA AG
Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen
13 March 2023
APONTIS PHARMA AG
Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen
20 February 2023
APONTIS PHARMA AG
Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen
11 November 2022
APONTIS PHARMA AG
Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen
8 November 2022
APONTIS PHARMA AG
Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen
16 August 2022
APONTIS PHARMA AG
Original-Research: Apontis Pharma AG (von Montega AG): Kaufen
11 May 2022
APONTIS PHARMA AG
Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen
19 April 2022
APONTIS PHARMA AG
Original-Research: APONTIS PHARMA AG (von Montega AG): Kaufen
Latest News
News Functions
Additional Functions
21 November 2024
APONTIS PHARMA AG
APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentiva’s Voluntary Public Purchase Offer Waived
7 November 2024
APONTIS PHARMA AG
APONTIS PHARMA reports profitable revenue growth for Single Pill combinations in 9M 2024 – revenue guidance adjusted
30 October 2024
APONTIS PHARMA AG
Management Board and Supervisory Board of APONTIS PHARMA AG recommend accepting Zentiva’s public tender offer
16 October 2024
APONTIS PHARMA AG
APONTIS PHARMA and Zentiva entered into partnership for future growth – Zentiva will launch a voluntary public purchase offer
APONTIS PHARMA AG
APONTIS PHARMA and Zentiva enter into investment agreement – Zentiva will launch a voluntary public purchase offer
9 August 2024
APONTIS PHARMA AG
APONTIS PHARMA with profitable revenue growth for Single Pill combinations in the first half of 2024 – forecast for the full year confirmed
Upcoming Events
Event Functions
Additional Functions
Latest Reports
News Functions
Additional Functions
9 August 2024
APONTIS PHARMA AG
Half-yearly financial statements 2024
28 March 2024
APONTIS PHARMA AG
Annual financial statements 2023
10 August 2023
APONTIS PHARMA AG
Half-yearly financial statements 2023